Bright Minds Biosciences Inc. DRUG
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.20% | 109.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.00% | 130.24% | |||
| Operating Income | 26.00% | -130.24% | |||
| Income Before Tax | 77.28% | -40.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 77.28% | -40.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 77.28% | -40.51% | |||
| EBIT | 26.00% | -130.24% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 77.83% | -13.72% | |||
| Normalized Basic EPS | 77.82% | -13.71% | |||
| EPS Diluted | 77.83% | -13.72% | |||
| Normalized Diluted EPS | 77.82% | -13.71% | |||
| Average Basic Shares Outstanding | 2.51% | 23.56% | |||
| Average Diluted Shares Outstanding | 2.51% | 23.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||